Participated · Equity · Jul 2026

410 Medical develops advanced resuscitation technologies centered on its lead product, the LifeFlow infuser, which received FDA clearance in 2016. LifeFlow is used by more than 500 hospitals and EMS agencies and has been used to treat nearly 80,000 patients experiencing conditions like sepsis and hemorrhagic shock. The company was founded in 2013 and is based in North Carolina. In July 2026 410 Medical raised $12 million in growth financing led by Orlando Health Ventures to scale commercial operations and accelerate LifeFlow adoption. The company is also investing in a next-generation LifeFlow device planned for launch in 2027. The financing was supported by a syndicate of hospital and healthcare investors, reflecting continued commercial momentum.

Participated · Series A · Jun 2026

Icarus Medical develops a new class of orthopedic bracing technologies that combine biomechanics, software, and additive manufacturing to address osteoarthritis, post-operative recovery, neurological conditions, and complex lower-extremity mobility challenges. Key products include the Ascender Knee Brace for patellofemoral and multicompartment osteoarthritis and the Adonis Joint Distraction Knee Brace for unicompartmental osteoarthritis. The company designs and manufactures its products in Charlottesville, Virginia, and plans to expand manufacturing capacity as part of its growth strategy. Icarus intends to advance clinical validation of its devices while accelerating commercialization across the U.S. and hiring additional personnel. Its recent recognition includes placement on the Inc. 5000 list for 1,283% three-year growth and the 2026 CBIC Startup of the Year Award.

Participated · Equity · Mar 2026

Verily builds an AI-native precision health platform that transforms multimodal health data into insights, models, and actions intended to make healthcare more personalized, predictive, and precise. The company plans to accelerate that platform strategy following a $300 million investment and a legal restructure from an LLC to Verily Health Inc. Verily has been expanding commercial relationships—announcing collaborations with Samsung’s Galaxy Watch, Salesforce, UCHealth, the University of Colorado Anschutz, and RefinedScience—for biomarker development, clinical research acceleration, and enterprise precision health solutions. Alphabet remains an investor and, after the round, holds a significant minority position rather than a controlling stake. The company positions itself at the intersection of technology, data science, and healthcare to drive AI-enabled research and care transformation.

Participated · Series E · Mar 2026

Monteris Medical develops the NeuroBlate System, a robotically controlled, MR-guided laser ablation platform that enables minimally invasive treatment of brain tumors and drug-resistant epilepsy in patients aged two and older. The technology, deployed in nearly 130 health systems across North America, delivers precise laser energy to destroy abnormal brain tissue while minimizing collateral damage. Clinical studies cited by the company report short hospital stays, low complication rates, and outcomes comparable to open resection. Monteris plans to use new capital to expand its U.S. commercial footprint, advance technology development, conduct additional clinical research, and pursue geographic expansion. Management reports strong operational results with a near-term pathway to profitability and positive cash flow. The NeuroBlate platform is currently the only LITT system with a robotic interface and published prospective clinical data supporting its safety and efficacy.

Participated · Series A · Feb 2026

Abram Scientific is a Menlo Park-based medical device company focused on next-generation coagulation diagnostics. Its flagship product, CoagCare™, is a handheld meter and single-use test card that delivers a full viscoelastic profile of the blood-clotting cascade, including fibrinolysis, in under ten minutes from a single drop of blood. This speed markedly improves on existing thromboelastography and thromboelastometry systems, which often require 30–60 minutes, making CoagCare suitable for critical settings such as trauma bays, operating rooms, ambulances, and MEDEVAC helicopters. The platform’s portability and vibration-insensitive design aim to extend laboratory-grade accuracy to remote or pre-hospital environments. Abram holds 17 issued patents covering the technology and is working toward U.S. FDA 510(k) clearance. The newly raised capital will fund product development, clinical validation, and regulatory submissions. Strategic collaborations with Octapharma and the University of Colorado Anschutz provide additional clinical expertise and commercialization pathways.